Skandinaviska Enskilda Banken AB publ Lowers Stake in Amgen Inc. $AMGN

Skandinaviska Enskilda Banken AB publ reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 36.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 157,318 shares of the medical research company’s stock after selling 91,177 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Amgen were worth $44,372,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Summitry LLC bought a new position in Amgen in the third quarter valued at $211,000. M&G PLC boosted its holdings in shares of Amgen by 3.8% in the 3rd quarter. M&G PLC now owns 454,584 shares of the medical research company’s stock worth $128,193,000 after purchasing an additional 16,646 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares in the last quarter. Texas Yale Capital Corp. increased its position in shares of Amgen by 0.5% during the 3rd quarter. Texas Yale Capital Corp. now owns 10,247 shares of the medical research company’s stock valued at $2,892,000 after purchasing an additional 50 shares during the last quarter. Finally, MRA Advisory Group raised its holdings in shares of Amgen by 6.9% during the 3rd quarter. MRA Advisory Group now owns 1,064 shares of the medical research company’s stock valued at $300,000 after buying an additional 69 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 0.8%

Shares of Amgen stock opened at $369.19 on Tuesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12. The company’s 50 day moving average price is $338.43 and its 200-day moving average price is $314.29. The stock has a market capitalization of $198.80 billion, a price-to-earnings ratio of 25.94, a P/E/G ratio of 3.78 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Morgan Stanley upped their target price on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Leerink Partners boosted their price objective on shares of Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Scotiabank assumed coverage on shares of Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 7th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $354.04.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.69% of the stock is owned by insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.